VERTEX PHARMACEUTICALS INC / MA Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax of $14.30 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2019-12-31 was $1.50M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2019-09-30 was $2.20M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2019-06-30 was $1.80M, a 800.00% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2018-06-30 was $200.00K.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for fiscal 2020 was $14.30M, a 104.29% increase from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for fiscal 2019 was $7.00M.
- VERTEX PHARMACEUTICALS INC / MA other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for fiscal 2018 was -$7.10M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $14.30M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $3.70M derived: sum of 2 quarters · filed 2021-02-11 | $5.50M derived: sum of 3 quarters · filed 2021-02-11 | $7.00M 10-K · filed 2021-02-11 |
| 2019-09-30 | $2.20M 10-Q · filed 2019-10-31 | $4.00M derived: sum of 2 quarters · filed 2019-10-31 | $5.50M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $1.80M 10-Q · filed 2019-08-01 | $3.30M 10-Q · filed 2019-08-01 | ||
| 2018-12-31 | -$7.10M 10-K · filed 2021-02-11 | |||
| 2018-06-30 | $200.00K 10-Q · filed 2019-08-01 | $500.00K 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |